Division of Cardiac Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ann Thorac Surg. 2020 Apr;109(4):1120-1126. doi: 10.1016/j.athoracsur.2019.10.087.
Frailty is increasingly recognized as an important prognostic marker in surgical populations. The effects of frailty on outcomes after mitral valve replacement (MVR) is less clear given the inherent complexity of this patient population. We evaluated the influences of frailty on outcomes and readmission rates after MVR.
Adult patients undergoing isolated MVR were queried from the National Readmissions Database from 2010 to 2014. Frailty was defined using the Johns Hopkins Adjusted Clinical Groups frailty-defining diagnoses indicator, a validated instrument developed for use in health administrative data. Multivariable logistic regression was used to determine hospital- and patient-level risk factors for readmission, postoperative complications, and death.
Among 50,410 patients who underwent MVR, 7.9% met frailty criteria. Frail patients were more likely to be older, have nonprivate insurance, an index admission from the emergency department, and teaching hospital care (all P < .001). Frail patients had significantly more postoperative complications (77% vs 47%, P < .001), more discharges to a facility (50% vs 21%, P < .001), and higher in-hospital mortality (12% vs 4%, P < .001). Index hospitalization costs were almost doubled in frail patients, and of those who survived to discharge, 30-day readmissions were more frequent (28% vs 20%, P < .001). Frailty independently increased the risk of index hospitalization composite complications (adjusted odds ratio [AOR], 3.28; 95% confidence interval [CI], 2.61-4.12), in-hospital mortality (AOR, 2.35; 95% CI, 1.90-2.92), and 30-day readmission (AOR, 1.47; 95% CI, 1.20-1.78).
Frailty is an independent predictor of morbidity, death, and increased costs after MVR. Frailty metrics should be increasingly understood among patients requiring mitral valve intervention as percutaneous approaches for intervention become increasingly used.
衰弱日益被认为是手术人群中重要的预后标志物。鉴于此类患者群体的固有复杂性,衰弱对二尖瓣置换术(MVR)后结局的影响尚不清楚。我们评估了衰弱对 MVR 后结局和再入院率的影响。
从 2010 年至 2014 年,从国家再入院数据库中查询接受单纯 MVR 的成年患者。使用约翰霍普金斯调整临床组衰弱定义诊断指标来定义衰弱,这是一种用于健康管理数据的经过验证的工具。多变量逻辑回归用于确定医院和患者水平的再入院、术后并发症和死亡的危险因素。
在 50410 例接受 MVR 的患者中,7.9%符合衰弱标准。虚弱患者更可能年龄较大、没有私人保险、急诊入院和教学医院治疗(均 P <.001)。虚弱患者术后并发症明显更多(77% vs 47%,P <.001),更多出院至医疗机构(50% vs 21%,P <.001),院内死亡率更高(12% vs 4%,P <.001)。虚弱患者的住院费用几乎翻了一番,在存活出院的患者中,30 天再入院更为频繁(28% vs 20%,P <.001)。衰弱独立增加了指数住院综合并发症的风险(调整后的优势比[OR],3.28;95%置信区间[CI],2.61-4.12)、院内死亡率(OR,2.35;95%CI,1.90-2.92)和 30 天再入院(OR,1.47;95%CI,1.20-1.78)。
衰弱是 MVR 后发病率、死亡率和增加费用的独立预测因素。随着经皮介入治疗方法的应用越来越广泛,需要二尖瓣干预的患者应越来越了解衰弱指标。